-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu (600079.SH): Briprazole tablets obtained drug registration certificate

Zhitongcaijing·08/06/2026 07:41:16
Listen to the news

Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Registration Certificate” for bryprazole tablets approved and issued by the State Drug Administration.

Briprazole tablets are mainly used to treat schizophrenia in adults. Yichang Renfu submitted a marketing license application for briprazole tablets to the State Drug Administration in April 2025 and was accepted. Up to now, the project has invested about 18 million yuan in R&D.